David Bottomley

7.8k total citations · 3 hit papers
58 papers, 2.4k citations indexed

About

David Bottomley is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Radiation. According to data from OpenAlex, David Bottomley has authored 58 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Pulmonary and Respiratory Medicine, 18 papers in Radiology, Nuclear Medicine and Imaging and 15 papers in Radiation. Recurrent topics in David Bottomley's work include Prostate Cancer Treatment and Research (40 papers), Prostate Cancer Diagnosis and Treatment (31 papers) and Radiopharmaceutical Chemistry and Applications (16 papers). David Bottomley is often cited by papers focused on Prostate Cancer Treatment and Research (40 papers), Prostate Cancer Diagnosis and Treatment (31 papers) and Radiopharmaceutical Chemistry and Applications (16 papers). David Bottomley collaborates with scholars based in United Kingdom, United States and Sweden. David Bottomley's co-authors include Bashar Al‐Qaisieh, Brendan Carey, D. Ash, Matthew R. Sydes, Jeremy Millar, Mahesh Parmar, John M. Russell, Richard Cowan, David P. Dearnaley and Edwin Aird and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and The Journal of Urology.

In The Last Decade

David Bottomley

57 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

2007 686 citations David P. Dearnaley, Matthew R. Sydes et al. The Lancet Oncology profile →
Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial

2014 344 citations David P. Dearnaley, Gordana Jovic et al. The Lancet Oncology profile →
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial

2014 290 citations Peter Hoskin, Oliver Sartor et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Bottomley United Kingdom	21	2.1k	1.1k	669	371	262	58	2.4k
Graeme Duncan Canada	19	1.8k 0.9×	661 0.6×	242 0.4×	452 1.2×	298 1.1×	35	2.1k
Keen Hun Tai Australia	18	963 0.5×	609 0.6×	371 0.6×	129 0.3×	191 0.7×	30	1.3k
Eric Berthelet Canada	23	751 0.4×	464 0.4×	353 0.5×	402 1.1×	437 1.7×	78	1.7k
Peter F. Orio United States	22	1.2k 0.6×	513 0.5×	239 0.4×	226 0.6×	254 1.0×	138	1.6k
Sergio Faria Canada	23	1.2k 0.6×	790 0.7×	522 0.8×	215 0.6×	370 1.4×	91	1.8k
L.E.C.M. Blank Netherlands	21	1.9k 0.9×	537 0.5×	217 0.3×	366 1.0×	447 1.7×	44	2.6k
Thomas P. Shakespeare Australia	19	690 0.3×	347 0.3×	291 0.4×	225 0.6×	286 1.1×	85	1.3k
Gregor Goldner Austria	24	1.1k 0.5×	979 0.9×	681 1.0×	144 0.4×	361 1.4×	65	1.8k
David Beyer United States	24	2.3k 1.1×	1.7k 1.6×	716 1.1×	106 0.3×	331 1.3×	80	2.9k
Oren Cahlon United States	24	1.5k 0.7×	998 0.9×	536 0.8×	498 1.3×	569 2.2×	105	2.5k

Countries citing papers authored by David Bottomley

Since Specialization

Citations

This map shows the geographic impact of David Bottomley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Bottomley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Bottomley more than expected).

Fields of papers citing papers by David Bottomley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Bottomley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Bottomley. The network helps show where David Bottomley may publish in the future.

Co-authorship network of co-authors of David Bottomley

This figure shows the co-authorship network connecting the top 25 collaborators of David Bottomley. A scholar is included among the top collaborators of David Bottomley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Bottomley. David Bottomley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Никитин, А. А., et al.. (2026). Structural and isotopic peculiarities of a Сhernobyl fuel “hot” particle. Journal of Environmental Radioactivity. 294. 107926–107926.

Payne, Heather, et al.. (2022). White Rose Research Online (University of Leeds, The University of Sheffield, University of York). 2 indexed citations

Slevin, Finbar, Bashar Al‐Qaisieh, Peter Bownes, et al.. (2020). Ten-year longitudinal health-related quality of life following iodine-125 brachytherapy monotherapy for localized prostate cancer. Journal of Contemporary Brachytherapy. 12(6). 540–546. 8 indexed citations

Slevin, Finbar, S. Rodda, Peter Bownes, et al.. (2019). A comparison of outcomes for patients with intermediate and high risk prostate cancer treated with low dose rate and high dose rate brachytherapy in combination with external beam radiotherapy. Clinical and Translational Radiation Oncology. 20. 1–8. 15 indexed citations

Parker, Christopher, Steven E. Finkelstein, Jeff M. Michalski, et al.. (2016). Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial. European Urology. 70(5). 875–883. 51 indexed citations

Musunuru, Hima Bindu, Malcolm Mason, Louise Murray, et al.. (2014). Second Primary Cancers Occurring after I-125 Brachytherapy as Monotherapy for Early Prostate Cancer. Clinical Oncology. 26(4). 210–215. 15 indexed citations

Slevin, Finbar, et al.. (2014). Hyponatraemic seizures following prostate brachytherapy. Journal of Radiotherapy in Practice. 13(3). 371–374. 1 indexed citations

Hoskin, Peter, Oliver Sartor, Joe M. O’Sullivan, et al.. (2014). Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. The Lancet Oncology. 15(12). 1397–1406. 290 indexed citations breakdown →

Ahmed, Hashim U., Viktor Berge, David Bottomley, et al.. (2014). Can we deliver randomized trials of focal therapy in prostate cancer?. Nature Reviews Clinical Oncology. 11(8). 482–491. 47 indexed citations

10.

Dearnaley, David P., Gordana Jovic, Isabel Syndikus, et al.. (2014). Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. The Lancet Oncology. 15(4). 464–473. 344 indexed citations breakdown →

11.

Tran, Anna, R. Swindell, Peter Hoskin, et al.. (2013). Biochemical outcomes for patients with intermediate risk prostate cancer treated with I-125 interstitial brachytherapy monotherapy. Radiotherapy and Oncology. 109(2). 235–240. 13 indexed citations

12.

Parker, Chris, Daniel Heinrich, David Bottomley, et al.. (2013). Effects of radium-223 dichloride (Ra-223) on health-related quality of life (QOL) outcomes in the phase 3 ALSYMPCA study in patients with castration-resistant prostate cancer (CRPC) and bone metastases. European Journal of Cancer. 49. 2 indexed citations

13.

Sartor, Oliver, Daniel Heinrich, Joe M. O’Sullivan, et al.. (2012). Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Interim results of a phase III trial (ALSYMPCA).. Journal of Clinical Oncology. 30(15_suppl). 4551–4551. 12 indexed citations

14.

Munro, Nicholas P., Bashar Al‐Qaisieh, Peter Bownes, et al.. (2010). Outcomes from Gleason 7, intermediate risk, localized prostate cancer treated with Iodine-125 monotherapy over 10years. Radiotherapy and Oncology. 96(1). 34–37. 27 indexed citations

15.

Mitchell, D., David Bottomley, Peter Hoskin, et al.. (2008). Report on the Early Efficacy and Tolerability of I125 Permanent Prostate Brachytherapy from a UK Multi-institutional Database. Clinical Oncology. 20(10). 738–744. 8 indexed citations

16.

Dearnaley, David P., Matthew R. Sydes, John D. Graham, et al.. (2007). Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. The Lancet Oncology. 8(6). 475–487. 686 indexed citations breakdown →

17.

Ash, D., et al.. (2007). A prospective analysis of long-term quality of life after permanent I-125 brachytherapy for localised prostate cancer. Radiotherapy and Oncology. 84(2). 135–139. 59 indexed citations

18.

Al‐Qaisieh, Bashar, D. Ash, David Bottomley, & Brendan Carey. (2002). Impact of prostate volume evaluation by different observers on CT-based post-implant dosimetry. Radiotherapy and Oncology. 62(3). 267–273. 64 indexed citations

19.

Clark, Ian, et al.. (2001). Iodine Systematics in the Ground Water of a Natural Setting. AGUFM. 2001. 1 indexed citations

20.

Al‐Booz, Hoda, D. Ash, David Bottomley, & B. Carey. (1999). Short‐term morbidity and acceptability of ¹²⁵ iodine implantation for localized carcinoma of the prostate. British Journal of Urology. 83(1). 53–56. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact